Urinary peptidome and diabetic retinopathy in the DIRECT‐Protect 1 and 2 trials

Abstract

Given the association of diabetic retinopathy (DR) and kidney disease, we investigated the urinary peptidome to presence and deterioration of DR in a post hoc analysis of trials investigating the effect of candesartan on progression of DR in type 1 and type 2 diabetes, respectively.